HUMA (HUMA) fluctuates 42.3% in 24 hours: Rapid retracement after technical breakthrough and spot buying momentum
Bitget Pulse2026/03/12 21:14Volatility Brief
In the past 24 hours, HUMA’s price rose from a low of $0.01616 to a high of $0.023, with the current quote at $0.01711, experiencing an amplitude of 42.3%. The 24-hour trading volume is approximately $74.75 million, with a volume/market cap ratio of 149.41%, indicating high activity.
Brief Analysis of Anomaly Reasons
- The price broke out of a multi-day consolidation range in the morning, accompanied by liquidity sweeps and a surge in spot buying on Binance/Bybit, driving a 10% increase. The 24-hour trading volume once rose to $108.85 million (+38.8%).
- There was no official announcement, on-chain whale large transfers, or mainstream news event coverage; the anomaly was mainly technically driven.
Market Views and Outlook
Community sentiment is 85% bullish. Traders point out a higher-lows structure and strong buying, suggesting a long position at $0.0188–$0.0192 targeting $0.023, while some opinions caution about a possible pullback to $0.0178 support if there is rejection near $0.0212.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Qualcomm (QCOM.US) Snapdragon Summit Preview: 2nm Dual-Chip Debuts, AI Diversification Narrative Faces Key Verification
Qualcomm is scheduled to hold its annual Snapdragon Summit in Maui, Hawaii, from September 22 to 24 local time.
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash
